Multitracer PET/CT Signature Unmasking Extramedullary Multiple Myeloma Masquerading as PEComa
Clinical Nuclear Medicine Open · 2026-12 · 3 (4)
DOI: 10.1097/nm9.0000000000000097 ↗Abstract
A 61-year-old man with a two-year diagnosis of PEComa on Pazopanib was referred for response assessment. ¹⁸F-FDG PET/CT showed disease progression with a bulky abdominal mass (SUVmax 16.6) and lytic skeletal lesions. ⁶⁸Ga-FAPI PET/CT, performed given the mesenchymal diagnosis, was completely negative—a paradox incompatible with PEComa, an SMA/Vimentin-positive tumor expected to show FAP-inhibitor avidity. This FAPI-negative paradox is itself a positive exclusionary signal, prompting re-biopsy that confirmed a lambda-restricted plasma cell neoplasm (CD138+, MUM1+, CD56+). ⁶⁸Ga-Pentixafor PET/CT corroborated intense CXCR4 avidity, establishing extramedullary multiple myeloma. The FDG+/FAPI−/Pentixafor+ signature is a noninvasive fingerprint of plasma cell malignancy.
EUVIMED